Adimab Announces 2021 Clinical Pipeline Update with 12 New Partner Programs
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced that 12 new partner programs entered clinical development in 2021. These programs include initiatives by Biotheus, Dragonfly, IASO, Iconic, Innovent, Mapp Biopharmaceutical, and Surface Oncology, bringing the total number of Adimab partner programs that have entered the clinic to 55.
The most advanced program from Adimab’s platform is Tyvyt® (Sintilimab), currently marketed in China by Innovent and Lilly. In 2021, Innovent and Lilly filed a Biologics License Application (BLA) with the FDA for approval in the United States. There are currently six additional programs in pivotal trials.
Guy Van Meter, Chief Business Officer of Adimab, expressed excitement over the advancement of many partners’ programs into the clinic, noting that 45 new programs have entered clinical trials over the last four years alone. He highlighted the remarkable success these programs are achieving in the clinic.
In 2021, Adimab partners exercised 10 commercial licenses to advance programs into development, increasing the total number of optioned programs to more than 85. Partners exercising commercial options in 2021 included Biotheus, Bristol Myers Squibb, IGM Biosciences, Immunitas Therapeutics, Mapp Biopharmaceutical, Regeneron, Sanofi, and Therini, among others.
Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab, emphasized the company's goal of long-term value creation and alignment with its partners, stating that Adimab wins when its partners win. This philosophy has focused the organization on quality and enabling clinical success for its partners.
Adimab is the leading provider of therapeutic antibody discovery and engineering technologies, focusing solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with 95 pharmaceutical and biotechnology companies, generating 425 therapeutic programs, 55 clinical programs, and its first approved product. The Adimab technology has been transferred and implemented at major pharmaceutical companies, including Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda.